The “Spot 14” Gene Resides on the Telomeric End of the 11q13 Amplicon and is Expressed in Lipogenic Breast Cancers: Implications for Control of Tumor Metabolism by Moncur, Joel T et al.
Dartmouth College 
Dartmouth Digital Commons 
Open Dartmouth: Peer-reviewed articles by 
Dartmouth faculty Faculty Work 
6-1998 
The “Spot 14” Gene Resides on the Telomeric End of the 11q13 
Amplicon and is Expressed in Lipogenic Breast Cancers: 
Implications for Control of Tumor Metabolism 
Joel T. Moncur 
Dartmouth College 
Jonathan P. Park 
Dartmouth College 
Vincent A. Memoli 
Dartmouth College 
T. K. Mohandas 
Dartmouth College 
William B. Kinlaw 
Dartmouth College 
Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa 
 Part of the Medical Pathology Commons, Medical Physiology Commons, and the Neoplasms 
Commons 
Dartmouth Digital Commons Citation 
Moncur, Joel T.; Park, Jonathan P.; Memoli, Vincent A.; Mohandas, T. K.; and Kinlaw, William B., "The “Spot 
14” Gene Resides on the Telomeric End of the 11q13 Amplicon and is Expressed in Lipogenic Breast 
Cancers: Implications for Control of Tumor Metabolism" (1998). Open Dartmouth: Peer-reviewed articles 
by Dartmouth faculty. 1463. 
https://digitalcommons.dartmouth.edu/facoa/1463 
This Article is brought to you for free and open access by the Faculty Work at Dartmouth Digital Commons. It has 
been accepted for inclusion in Open Dartmouth: Peer-reviewed articles by Dartmouth faculty by an authorized 
administrator of Dartmouth Digital Commons. For more information, please contact 
dartmouthdigitalcommons@groups.dartmouth.edu. 
Proc. Natl. Acad. Sci. USA
Vol. 95, pp. 6989–6994, June 1998
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The ‘‘Spot 14’’ gene resides on the telomeric end of the 11q13
amplicon and is expressed in lipogenic breast cancers:
Implications for control of tumor metabolism
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ABSTRACT Enhanced long chain fatty acid synthesis
may occur in breast cancer, where it is necessary for tumor
growth and predicts a poor prognosis. ‘‘Spot 14’’ (S14) is a
carbohydrate- and thyroid hormone-inducible nuclear protein
specific to liver, adipose, and lactating mammary tissues that
functions to activate genes encoding the enzymes of fatty acid
synthesis. Amplification of chromosome region 11q13, where
the S14 gene (THRSP) resides, also predicts a poor prognosis
in breast tumors. We localized the S14 gene between markers
D11S906 and D11S937, at the telomeric end of the amplified
region at 11q13, and found that it was amplified and expressed
in breast cancer-derived cell lines. Moreover, concordant
expression of S14 and a key lipogenic enzyme (acetyl-CoA
carboxylase) in a panel of primary breast cancer specimens
strongly supported a role for S14 as a determinant of tumor
lipid metabolism. S14 expression provides a pathophysiolog-
ical link between two prognostic indicators in breast cancer:
enhanced lipogenesis and 11q13 amplification.
‘‘Spot 14’’ (S14) is a small ('17 kDa), acidic (pI 4.9) protein
with no similarity to other mammalian gene products. The S14
gene is specifically expressed in tissues that produce lipids for
use as a metabolic fuel, including lactating mammary, white
and brown adipose tissue, and liver (1). In liver, its expression
is rapidly induced by stimuli for increased long chain fatty acid
synthesis, including thyroid hormone, glucose, and insulin (1),
and is inhibited by glucagon and other stimuli that reduce
lipogenesis (2). These observations, coupled with immunohis-
tochemical localization of S14 to the nucleus, prompted the
hypothesis that S14 functioned in the tissue-specific regulation
of genes encoding the enzymes of lipid synthesis (3). This
concept was supported by experiments using rat hepatocytes in
primary culture that were treated with a S14 antisense oligo-
nucleotide during exposure to the lipogenic stimuli of glucose
and thyroid hormone (4). Antisense-mediated disruption of
S14 induction inhibited the induction of lipogenesis. This result
was explained by impaired expression of the lipogenic enzymes
and their respective mRNAs. Transfection studies showed that
this effect was attributable to reduced transcription (5).
The role of S14 in the tissue-specific transduction of hor-
monal- and diet-induced signals for activation of genes in-
volved in lipogenesis raised the hypothesis that aberrant S14
expression is important in conditions with abnormal lipid
metabolism. One such condition is breast cancer. Overexpres-
sion of fatty acid synthase (FAS), a major enzyme of fatty acid
biosynthesis, is a marker for poor prognosis in breast tumors
(6, 7). FAS is also important for tumor metabolism and growth.
Pharmacological inhibition of fatty acid synthesis in breast
cancer cells with FAS overexpression caused reduced growth
and programmed cell death, an effect that was reversed by
addition of palmitic acid to the growth media (8, 9). Increased
FAS expression also occurs in primary breast tumors (9). The
mechanism underlying enhanced expression of lipogenic en-
zymes in the tumors is unknown.
We localized the human S14 gene (THRSP) to the long arm
of chromosome 11 (11q13.5) (10), which has been confirmed
independently (11). Amplification at 11q13 occurs in '20% of
breast cancers, and this amplification predicts a poor prognosis
(12, 13). It is believed that 11q13 amplification results in
overexpression of genes that are critical for tumor growth. We
therefore considered the possibility that the S14 gene is
amplified and overexpressed in breast tumors and that this
could result in increased tumor lipogenesis. Currently, cyclin
D1 (CCND1) and EMS1 are the only genes known to be both
amplified and expressed in breast tumors with 11q13 amplifi-
cation (reviewed in ref. 14). Cyclin D1 is a nuclear protein that
regulates the transition from the G1 to the S phase of the cell
cycle and is an obvious candidate oncogene. Transgenic mice
with constitutive CCND1 overexpression exhibited mammary
neoplasia (15). EMS1 encodes a c-src substrate associated with
adherence of tumor cells to the extracellular substratum (16,
17). It has been speculated that this protein could mediate
interactions with the extracellular matrix that may be impor-
tant for metastasis (14). Several features of the 11q13 amplicon
have raised the possibility that other genes important to tumor
growth must be expressed from it. First, the 11q13 amplicon is
consistently large (reportedly up to 5 Mbp) (18, 19). Second,
amplification at 11q13 is discontinuous (20, 21). Third, some
breast cancer cell lines with 11q13 amplification do not exhibit
overexpression of CCND1 (22). Fourth, overexpression of
CCND1 in stably transfected human mammary epithelial cells
(23) or diploid fibroblasts (24) inhibited rather than acceler-
ated cell growth.
We now report a more precise localization of the human S14
gene and show that it was both amplified and expressed in
several breast cancer-derived cell lines. Most importantly, S14
was expressed in the majority of primary breast cancer spec-
imens, and its expression was highly concordant with that of
acetyl-CoA carboxylase (ACC), a rate-determining enzyme of
fatty acid biosynthesis. S14 therefore provides a critical met-
abolic link between two established prognostic indicators in
human breast cancers: 11q13 amplification and enhanced fatty
acid formation.
METHODS
PCR Screening of Yeast Artificial Chromosomes (YACs).
YAC 965-F-10 (1,170 kbp), 745-E-12 (990 kbp), and 796-E-11
© 1998 by The National Academy of Sciences 0027-8424y98y956989-6$2.00y0
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(1,040 kbp) (Research Genetics, Huntsville, AL) were selected
based on their localization to 11q13.5 and lack of chimerism.
A cytogenetic map of the sequence-tagged sites and genes
residing on these YACs was compiled by Kelley and coworkers
(25) (Fig. 1A). YAC DNA was harvested as described (26).
PCR was performed in a Perkin–Elmer Thermal Cycler (1 min
at 94°C, then 30 cycles of 30 sec at 94°C, 30 sec at 65°C, 1 min
at 72°C ). Primers (Oligos, Etc., Wilsonville, OR) are defined
in Table 1.
Southern Blot Analysis. YAC 745-E-12 DNA in agarose
plugs (27) was digested with NotI and SalI (Boehringer Mann-
heim) and resolved by pulsed-field gel electrophoresis in 0.8%
agarose in 0.5X TrisyborateyEDTA buffer. Switching times
[PPI-200 Programmable Electrophoresis Controller (MJ Re-
search, Cambridge, MA)] were ramped from 40 sec to 6 min
at 5-sec intervals for 96 hr at 100 V. Southern blots were
probed with randomly primed (GIBCOyBRL), [a-32P]-labeled
PCR products from markers D11S906 and D11S937 (Research
Genetics) as well as a 345-bp product representing the S14
gene (Table 1).
Breast cancer cell line genomic DNA was isolated by using
the Puregene DNA Isolation Kit (Gentra Systems). Control
DNA was from human lymphocytes. DNA samples were
digested with EcoRI (Boehringer Mannheim) and blotted as
described. The probe for the uncoupling protein 3 (UCP3)
gene was a 260-bp PCR product (28). The control probe
targeted the T-cell antigen receptor constant b-chain gene
(TCRBC), located on chromosome 7q (29). Signals were
analyzed densitometrically [Personal Densitometer SI Model
375A (Molecular Dynamics)]; gene amplification was assessed
by calculating a signal ratio of S14:TCRBC, normalized to that
of control DNA.
Cell Culture. Cell lines were from the American Type
Culture Collection (ATCC). MDA-MB-134 cells were main-
tained in L-15 medium supplemented with 20% fetal calf
serum (FCS) and 30 ngyml epidermal growth factor (GIBCOy
BRL); MDA-MB-435s cells were maintained in L-15 medium
with 15% FCS, 2 mM L-glutamine, and 10 mgyml insulin;
MDA-MB-453 cells were maintained in L-15 medium with
10% FCS; MCF-7, SKBR3, and ZR-75-1 in DMEMyF12 were
maintained with 10% FCS, and T47D cells were maintained in
RPMI 1640 medium with 10% FCS, 2 mM L-glutamine, 1.5
gyliter sodium bicarbonate, 4.5 gyliter glucose, 10 mM Hepes,
1.0 mM sodium pyruvate, and 10 mgyml insulin. Penicillin and
streptomycin were added to all culture media.
Differential PCR. MDA-MB-134 genomic DNA was har-
vested by using the Trizol Reagent (GIBCOyBRL) and used
as PCR template as described (30) (94°C for 25 sec and 64°C
for 2.5 min 3 29 cycles). Control DNA was from normal
human lymphocytes. The interferon-g (IFNG) gene (chromo-
some 12q) was used as a reference in this experiment. Primers
are defined in Table 1.
Chromosome Analysis and Fluorescence in Situ Hybridiza-
tion. The probe for the S14 (THRSP) locus was an '80-kbp P1
clone (10) and biotin-labeled by nick translation (Bionick,
GIBCOyBRL). Chromosomes prepared by standard tech-
niques were conditioned by a 30 min, 37°C bath in 2X standard
sodium citrate followed by dehydration in EtOH, at 22°C, and
air dried. Slides were denatured in 70% formamidey2X stan-
dard sodium citrate followed by serial dehydration at 22°C. The
probe was denatured (70°C 3 5 min) and preannealed at 37°C
for 2 h. Hybridization solution contained 0.2-mg probe, 10 mg
of Cot-1 DNA (GIBCOyBRL), and 30 mg of herring sperm
DNA (GIBCOyBRL) in 15 ml of Hybrisol VII (Oncor) per
slide. The whole chromosome painting probe was from Oncor.
Hybridization conditions were as described (31).
Reverse Transcriptase–PCR (RT-PCR). Total RNA was
extracted with Trizol Reagent (GIBCOyBRL). Contaminating
DNA was digested with DNase I (GIBCOyBRL). RT-PCR
was performed using the SuperScript One-Step System
(GIBCOyBRL) using 100 ng of total RNA as template
(55°C 3 30 min and 94°C 3 2 min, followed by 37 cycles of
FIG. 1. Localization of the S14 gene to between D11S906 and D11S937. (A) A schematic representation of genes, sequence-tagged site markers,
and YACs that span 11q13.5 without regard to genetic or physical distance, based on a cytogenetic map by Kelley and coworkers (25). From their
study, the sequence-tagged siteygene content of YACs is represented with a solid circle; open circles indicate the markers not found on YAC
796-E-11 by those authors. In the current study, the S14 gene was amplified by PCR from YAC 745-E-12 and 796-E-11 but not 965-F-10. The
presence of D11S906 was confirmed on all three YACs, and D11S937 was found on YACs 745-E-12 and 796-E-11. (B) Restriction and Southern
blot analysis of YAC 745-E-12, resolved by pulsed-field gel electrophoresis. (C) An integrated map of the 11q13 amplicon, including centromeric
and telomeric portions separated by a dashed line. Genetic map information (Généthon) can be found at: http://www.genethon.fr/genethonoen.html.
Physical map information compiled from refs. 20 and 34–37. CEN, centromere; TEL, telomere; GARP, glycoprotein A repetitions predominant.
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94°C 3 15 sec, 65°C 3 30 sec, and 72°C 3 1 min). Primers are
listed in Table 1.
Western Blot. Primary cultures of human hepatocytes (Clo-
netics, Walkersville, MD) were maintained for 3 days in
modified William’s E medium (GIBCOyBRL) with 10% FCS,
50 nM thyroid hormone, and 27.5 mM glucose. Harvest of
proteins, SDS-PAGE (hepatocytes, 10 mgylane; MDA-MB-
134 cells, 15 mgylane) and Western blot with anti-S14 (residue
2–11 synthetic peptide) rabbit polyclonal antibody (1:1000
dilution) were as described (32).
Immunohistochemistry. We obtained 21 paraffin-embed-
ded primary breast cancer specimens (20 infiltrating ductal
carcinomas and one lobular carcinoma) from the tissue ar-
chives of the Dartmouth-Hitchcock Medical Center. Tissue
sections were steam-heated (20 min) and immunostained with
anti-S14 (2–11) antibody (1:200) or anti-ACC rabbit polyclonal
antibody (1:20) by using the avidin–biotin complex technique
as described (3, 33). Counterstaining was with hematoxylin (1
min). Immunostaining was defined as positive for S14 or ACC
if .20% of the tumor had discernible immunoreactivity at low
power (3100) in the nucleus (S14) or the cytoplasm (ACC).
RESULTS
Localization of the S14 gene. A band of the expected size for
S14 was amplified by PCR from YAC 745-E-12 and 796-E-11
but not from 965-F-10 DNA. The presence of D11S906 was
confirmed on all three YACs, and D11S937 was found on
YACs 745-E-12 and 796-E-11 (Fig. 1 A). Southern analysis of
SalI-digested YAC 745-E-12 DNA localized S14 to the same
'100-kbp band as D11S906 (Fig. 1B). Because S14 did not
reside on the centromeric-most 100 kbp of 745-E-12, as shown
by PCR analysis of overlapping YACs 965-F-10 (negative for
S14) and 745-E-12 (positive for S14), its colocalization to
within 100 kbp of D11S906 placed it on the telomeric side of
this sequence-tagged site. D11S937 is telomeric to S14 because
it localized to a different band ('200 kbp) than did S14.
Therefore, S14 is f lanked by D11S906 (centromeric) and
D11S937 (telomeric; Fig. 1C). This location is '550 kbp
downstream from the telomeric-most marker shown thus far to
be amplified in breast cancer [D11S833E (20, 21)]. Genetic
map information for this region indicates that S14 is '11–12
Mbp telomeric to CCND1. Digestion of 745-E-12 with NotI
revealed that D11S906, S14, and D11S937 were on the same
800-kbp DNA band (data not shown). Comparison with the
results observed with the SalI digestion limit the location of
D11S937 to a '600-kbp region telomeric to S14.
S14 Gene Amplification in Breast Cancer Cell Lines. South-
ern analysis revealed an increased S14:TCRBC ratio in 2 of 7
breast cancer cell lines. The S14 gene was amplified 6.1-fold in
MDA-MB-134 and 2.5-fold in T47D cells. The ratio of
S14:TCRBC was between 1.5 and 1.7 for MDA-MB-453,
SKBR3, and ZR-75-1 cells, a finding suggesting amplification.
There was no amplification in MDA-MB-435s and MCF-7
cells. These results and the amplification status of CCND1 and
EMS1 are summarized in Table 1. UCP3 recently was localized
to a region of 11q13 lying between EMS1 and the S14 gene
(28). Southern analysis with the UCP3 probe revealed no
amplification in any of the cell lines examined, including
MDA-MB-134 cells which exhibit amplification of CCND1,
EMS1, and S14 (data not shown).
Differential PCR using a reference gene on chromosome
12q independently confirmed the Southern blot results for
MDA-MB-134 cells, which used a reference gene from chro-
mosome 7q. The intensity of the 106-bp band representing the
S14 gene compared with the 76-bp product amplified from the
IFNG control was markedly increased for MDA-MB-134 DNA
compared with normal genomic DNA (Fig. 2B).
We undertook cytogenetic analysis of G-banded metaphases
from MDA-MB-435s and MDA-MB-134 cells. MDA-MB-435s
had a modal number of 53 chromosomes with numerous
rearranged chromosomes, including a few that appeared to be
partially derived from chromosome 11; no normal chromo-
some 11 was observed. The modal chromosome number of
MDA-MB-134 cells was 85 and appeared to be a near tet-
raploid version of the karyotype initially established for this
cell line (40). Of note were two apparently normal chromo-
some 11s in addition to three copies of a marker chromosome
characterized by a large homogeneously staining region (HSR)
on its long arm (data not shown). Paint analysis revealed that
the HSR was composed of interspersed chromosome 11 se-
quences, whereas the short arm of the marker chromosome
was not of chromosome 11 origin, consistent with a previous
characterization of this marker chromosome (41, 42).
Fluorescence in situ hybridization with the S14 probe re-
vealed hybridization to four chromosome-11-derived elements
in MDA-MB-435s chromosomes, without any evidence of S14
gene amplification (data not shown). Line MDA-MB-134,
however, showed the expected signal on the two normal
chromosome 11s at q13.5 as well as intense signals interspersed
in the HSR region of the marker chromosomes (Fig. 2C),
indicating amplification of these sequences beyond that ex-
pected by chromosome copy number.
Expression of S14 in Breast Cancer Cell Lines and Primary
Breast Cancers and Concordance with ACC Expression. RT-
PCR revealed a band of the expected size for S14 (345 bp) in
MDA-MB-134, MDA-MB-453, MCF-7, SKBR3, T47D, and
ZR-75-1 cell lines. The band representing MDA-MB-134
mRNA consistently demonstrated the strongest signal. The
only cell line that did not express S14 was MDA-MB-435s, a
line with no S14 gene amplification. The literature supports
overexpression of CCND1 in MDA-MB-134, MDA-MB-453,
and ZR-75-1 cells but not SKBR3 or T47D cells (22, 43, 44).
Overexpression of EMS1 occurs in MDA-MB-134, MDA-MB-
453, and ZR-75-1 but not MCF-7, SKBR3, or T47D cells.
Excess lipogenesis and FAS content are reported in progest-
erone-treated MCF-7, SKBR3, T47D, and ZR-75-1 cells (45).
Table 2. Amplification status of genes at 11q13
Cell line (ref.) CCND1 EMS1 S14
MDA-MB-134 (17, 21, 22) 1 1 1
MDA-MB-435s (39) 2 2 2
MDA-MB-453 (17, 22) 1 1 2*
MCF-7 (17) 2 1 2
SKBR3 (17, 22) 2 2 2*
T47D (17, 22, 38) 1y2 2 1
ZR-75-1 (17, 22) 1 1 2*
* The S14:TCRBC signal ratio was between 1.5 and 1.7.
Table 1. PCR primers, listed 59 to 39
Gene/size,
bp 59-Primer 39-Primer Gene reference
S14 345* CCAAGAACTGCCTGCTGACCGTCATGG GGATGTGATGGAGGCTGGAGAAGTGC 36-380, GDB:5446138
S14 106† GAGAATGGAACCGCAGAGACAGAGG GGATGTGATGGAGGCTGGAGAAGTGC 275-380, GDB:5446138
IFNG 75† CCCTCATCCAATGCTGGCAAACACC CCAATCCAAGCCTTCTCCCTAGAGC 5662-5736, GDB:119329
*Primers used for YAC screening and RT-PCR. This PCR product was used to probe Southern blots.
†Primers used for differential PCR. GDB, the Genome Database (http://gdbwww.gdb.org).
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Conservation of residues 2–11 in the rat and human S14
polypeptides allowed the use of an antibody raised against the
corresponding synthetic peptide for both Western and immu-
nohistochemical analysis of S14 expression in human tissues.
The utility of the antibody was validated by Western analysis
of primary cultures of human hepatocytes treated with thyroid
hormone and high glucose. This analysis revealed a band of the
expected size for human S14 (16.6 kDa). Western analysis of
MDA-MB-134 cells showed a band of the same size (Fig. 3B).
We further validated the anti-S14 (2–11) antibody by compar-
ing its pattern of immunohistochemical staining in hyperthy-
roid, carbohydrate-fed rat liver (Fig. 4A) with that of an
antibody raised against a fusion protein containing the entire
rat S14 protein as its carboxyl terminus (anti-GST-rS14 (3);
Fig. 4B). Control experiments validating the specificity of both
antibodies in Western analysis and the latter antibody in
immunohistochemistry of rat tissues have been published (32,
33). The two antibodies yielded identical patterns of marked
nuclear and weaker cytoplasmic immunoreactivity in a
perivenous zonal distribution, as reported (3). Staining of a
human, brown fat-derived tumor (hibernoma) with the anti-
S14 (2–11) antibody yielded marked nuclear staining (Fig. 4C),
as expected, that was attenuated by preincubation of the
anti-S14 (2–11) antibody with the GST-rS14 fusion protein.
This result was consistent with a recent report of S14 mRNA
expression in a human lipoma (46). The weak cytoplasmic
staining was unaffected by preincubation (Fig. 4D). Examina-
tion of five nonlactating human breast specimens yielded no
nuclear staining and weak, variable cytoplasmic staining (for
example, see Fig. 4E), whereas examination of four lactating
mammary samples revealed nuclear staining (for example, see
Fig. 4F). This result was consistent with the induction of S14
mRNA in lactating rat mammary gland (1). We analyzed 21
primary breast cancer specimens for S14 expression and found
nuclear staining in 14 (67%) (see example in Fig. 4 G and H).
The single lobular carcinoma was among the positive speci-
mens (not shown). Staining of selected tumors that exhibited
S14 immunoreactivity with antibody blocked with the GST-
rS14 fusion protein showed a markedly attenuated signal (Fig.
4I). We also stained the panel of 21 tumors for ACC to
investigate the metabolic relevance of S14 expression (example
in Fig. 4 J and K). Fifteen (71%) of the tumors exhibited
detectable ACC immunoreactivity, and this result was highly
concordant (86%, P , 0.05) with S14 expression (Fig. 4L).
DISCUSSION
The major findings in the current study were that the S14 gene
was both amplified and expressed in selected cell lines derived
from human breast cancer and that the S14 protein also was
readily detectable in two-thirds of a small sample of primary
breast cancer specimens. CCND1, EMS1, and S14 are cur-
rently the only genes shown to be expressed from the consis-
tently large 11q13 amplicon (14). The development of breast
tumors in transgenic mice with mammary-specific overexpres-
sion established the CCND1 as a mammary oncogene (15).
Our localization of the S14 gene between D11S906 and
D11S937 placed it at the opposite, telomeric end of the
amplicon from CCND1, raising the possibility that there was
selective pressure for S14 expression in concert with that for
CCND1. Published examples of breast cancers with amplifi-
cation of distal 11q13 but not of the more centromeric CCND1
region (17, 20) further raise the speculation that S14 could
FIG. 3. Expression of S14 in the majority of breast cancer cell lines. (A) RT-PCR analysis of RNA extracted from seven breast cancer cell lines.
p indicates that the sample was exposed to RNase before RT-PCR. (B) Western analysis of hyperthyroid (HT) human hepatocytes exposed to high
glucose, and MDA-MB-134 cells, using anti-S14 (2–11) IgG.
FIG. 2. Amplification of the S14 gene in a subset of breast cancer
cell lines. (A) Southern analysis of DNA from seven breast cancer cell
lines. (B) Differential PCR analysis of MDA-MB-134 cell DNA.
Genomic DNA from normal lymphocytes (control) or from MDA-
MB-134 cells was used as template for a multiplex PCR, using two
primers for the S14 gene (yielding a 106-bp product) and two for IFNG
(75 bp). In the first two lanes, omitting primers for S14 or IFNG
[indicated by (2)] resulted in the disappearance of the bands repre-
senting those genes. In the lane marked MDA-MB-134, the increased
S14:IFNG signal ratio compared with the control lane reflects the
presence of S14 gene amplification in those cells. (C) Fluorescence in
situ hybridization analysis of MDA-MB-134 chromosomes by using a
S14 probe. Arrows point to the HSR in the aberrant chromosome 11s,
previously observed on cytogenetic analysis. Intense fluorescent sig-
nals representing the S14 gene colocalize with the HSR. p denotes a
normal chromosome 11.
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provide an independent stimulus for tumor virulence. Indeed
D11S833E, the closest marker to the S14 gene reported to be
amplified in both breast cancer cell lines and primary breast
tumors (21), was the only marker at 11q13 that was amplified
in some tumors and in several tumors exhibited the greatest
fold amplification of the genes and markers studied (20). Our
finding that the UCP3 gene was not amplified in cell lines with
amplification of S14 and with reported amplification of
CCND1 and EMS1 confirmed the discontinuity of the 11q13
amplicon (17, 19–21). This finding raises the possibility of
independent selection for multiple genes expressed from the
amplicon.
Increased synthesis of long chain fatty acids may occur in
multiple common neoplasms, including those arising in the
breast (8), prostate (47), ovary (48), colon (49), and endome-
trium (9), and has been shown to confer a poor prognosis. The
mechanism underlying the overexpression of the lipogenic
enzymes is unknown. Kuhajda and coworkers found that
overexpression of FAS was not only a marker for unfavorable
prognosis but also was critical for tumor growth. This was
shown by treating breast cancer cells in tissue culture (9) or
ovarian cancer xenografts in nude mice (50) with cerulenin, a
pharmacological inhibitor of FAS. Cerulenin caused pro-
grammed cell death and slowed tumor growth. Cells were
rescued from the cerulenin effect by addition of palmitic acid
to the culture medium, indicating dependency on the fatty acid
for growth. However, it is unclear which cellular function(s)
crucial for growth depends on the ongoing supply of newly
synthesized long chain fatty acids. The requirement of fatty
acids for the synthesis of phospholipids used in plasma mem-
branes is a possibility (9).
A single genetic abnormality involving genes coding for the
enzymes cannot explain the enhanced lipid formation because
the genes for the three major lipogenic enzymes (ACC, FAS,
and ATP-citrate lyase) reside at different chromosomal loca-
tions (51–53). Previous work from our laboratory established
a role for S14 in the integrated switching of metabolism from
the fasted to the fed state, including induction of the lipogenic
enzymes, at the level of transcription (5). S14 protein exists
both as a homodimer and as a heterodimer with a currently
unidentified 36-kDa protein in vivo (54). Because S14 regulates
expression of the lipogenic enzymes, an increase in its expres-
sion provides a unitary explanation for the increased lipid
synthesis in tumors. Breast cancer patients with a poor prog-
nosis associated with either 11q13 amplification or increased
FAS expression may therefore represent overlapping clinical
groups.
Under physiological circumstances, S14 expression is in-
duced in rat liver by dietary carbohydrate and thyroid hormone
(55) and disappears in response to glucagon administration
(2), dietary polyunsaturated fatty acids (56), fasting, or dia-
betes mellitus (57). These effects are mediated at the tran-
scriptional level and reflect the array of response elements
present in the S14 gene promoter that allow it to integrate
multiple input signals initiated by fuel-related hormones and
dietary substrates. Little is known about the regulation of S14
expression in mammary tissue, except that it is induced during
the lipogenic demands of lactation in rat (1) and in human (Fig.
FIG. 4. Immunohistochemistry of hyperthyroid rat liver controls, nonlactating breast, lactating breast and 21 primary breast cancers for S14
and acetyl-CoA carboxylase. (A) Hyperthyroid, carbohydrate-fed rat liver probed with the anti-S14 (2–11) antibody; a region of the S14 peptide
that is homologous in rats and humans. (B) The same liver probed with the anti-GST-rS14 fusion protein antibody. (C) Human hibernoma
immunostained with the anti-S14 (2–11) antibody. (D) Hibernoma stained with the anti-S14 (2–11) antibody preincubated with the GST-rS14 fusion
protein. (E) Normal breast epithelium. (F) Lactating breast epithelium. (G and H) Example of infiltrating ductal carcinoma that has positive
immunoreactivity for S14 (I) The same tumor shown in G and H stained with the anti-S14 (2–11) antibody preincubated with the GST-rS14 fusion
protein. (J and K) Example of infiltrating ductal carcinoma with positive immunostaining for ACC (L) Concordance analysis of immunostaining
for S14 and ACC.
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4F). In breast cancer-derived cell lines that overexpress FAS,
the enzyme is inducible by progestin, indicating the presence
of an intact regulatory mechanism (43). It remains to be seen
whether this induction requires S14, analogous to its function
in the transduction of thyroid hormone-induced signals for
lipogenesis in liver. If so, hormonal or other means of manip-
ulating S14 expression could affect metabolism and growth of
selected tumors in a manner similar to that observed upon
pharmacological inhibition of lipogenesis.
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